In Q3 fiscal 2026 (the quarter ended July 31, 2026), Cooper Companies's largest business segment was CooperVision, with $717.00 million or 67% of revenue, down 0.2% from a year earlier. Next: Coopersurgical (33%).
By product or service, Sphere, Other brought in 35%, Toric and Multifocal brought in 33% and Office and Surgical brought in 20% of revenue in Q3 fiscal 2024.
By region, United States brought in 49%, Europe brought in 34% and Rest of World, Excluding United States and Europe brought in 18% of revenue in Q3 fiscal 2026.
The fastest-growing business segment from a year earlier was Coopersurgical (+2.1%).
From company filings, in USD; latest quarter ended July 31, 2026; quarterly data from Q1 fiscal 2018.

Fiscal quarters, from company filings
| Business segment | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q3 FY25 | Share |
|---|---|---|---|---|---|
| CooperVision | $717.0M | $723.5M | $695.1M | $718.4M | 67% |
| Coopersurgical | $349.2M | $358.0M | $329.0M | $341.9M | 33% |
In USD, fiscal quarters as reported; share = part of Q3 FY26 revenue.
| Product or service | Q3 FY24 | Q2 FY24 | Q1 FY24 | Q3 FY23 | Share |
|---|---|---|---|---|---|
| Sphere, Other | $349.2M | $325.6M | $324.2M | $333.7M | 35% |
| Toric and Multifocal | $326.4M | $310.3M | $297.3M | $296.5M | 33% |
| Office and Surgical | $197.9M | $182.9M | $191.1M | $178.4M | 20% |
| Fertility | $129.3M | $123.8M | $119.0M | $121.6M | 13% |
In USD, fiscal quarters as reported; share = part of Q3 FY24 revenue.
| Region | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q3 FY25 | Share |
|---|---|---|---|---|---|
| United States | $519.5M | $547.8M | $513.9M | $516.2M | 49% |
| Europe | $357.5M | $341.6M | $326.4M | $343.1M | 34% |
| Rest of World, Excluding United States and Europe | $189.2M | $192.1M | $183.8M | $201.0M | 18% |
In USD, fiscal quarters as reported; share = part of Q3 FY26 revenue.
CooperVision and Coopersurgical (as reported for Q3 fiscal 2026).
CooperVision: $717.00 million, or 67% of revenue, in Q3 fiscal 2026.
By revenue in Q3 fiscal 2024: Sphere, Other (35%), Toric and Multifocal (33%), Office and Surgical (20%) and Fertility (13%).
By region in Q3 fiscal 2026: United States (49%), Europe (34%) and Rest of World, Excluding United States and Europe (18%).
Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i
Fiscal quarter ended Jul 31, 2026
| Item | Revenue | Share |
|---|---|---|
| CooperVision | USD 717.00M | 67.2% |
| Coopersurgical | USD 349.20M | 32.8% |
Sum of items USD 1.07B. Shares are of the items shown. Click an item with › to see its parts.
Every item and period in one grid. Purple = calculated; "–" = not available.
| Item | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 | Q4 FY23 | Q3 FY23 | Q2 FY23 | Q1 FY23 | Q4 FY22 | Q3 FY22 | Q2 FY22 | Q1 FY22 | Q4 FY21 | Q3 FY21 | Q2 FY21 | Q1 FY21 | Q4 FY20 | Q3 FY20 | Q2 FY20 | Q1 FY20 | Q4 FY19 | Q3 FY19 | Q2 FY19 | Q1 FY19 | Q4 FY18 | Q3 FY18 | Q2 FY18 | Q1 FY18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CooperVision | 717.0M | 723.5M | 695.1M | 709.7M | 718.4M | 669.6M | 646.1M | 676.4M | 675.6M | 635.9M | 621.5M | 622.9M | 630.2M | 589.3M | 581.3M | 561.8M | 566.3M | 553.8M | 561.5M | – | 557.5M | 522.6M | 507.0M | 506.3M | 449.3M | 402.2M | 485.2M | 509.5M | 509.1M | 484.2M | 470.1M | 480.6M | 489.1M | 467.5M | 444.8M |
| Coopersurgical | 349.2M | 358.0M | 329.0M | 355.4M | 341.9M | 332.7M | 318.6M | 342.0M | 327.2M | 306.7M | 310.1M | 304.2M | 300.0M | 288.1M | 277.2M | 286.3M | 277.1M | 276.0M | 225.7M | – | 205.9M | 196.9M | 173.5M | 175.3M | 128.9M | 122.7M | 161.0M | 182.1M | 170.3M | 170.1M | 158.0M | 170.9M | 170.9M | 163.8M | 145.2M |